Company Overview
Snapshot
Founded in January 2019 by Yotam Hod, Gynica operates with 1–10 employees. The company has raised $4 million across two funding rounds. In March 2024, Gynica announced the initiation of its first-in-human clinical trial for a novel IntraVag© treatment designed for endometriosis.
Business overview
Gynica is a biotech company focused on improving women's health by developing safe, effective, non-hormonal, intra-vaginal therapeutic solutions for endometriosis. The company utilizes its proprietary IntraVag© technology, a non-invasive, self-administered drug delivery platform, to address the chronic and debilitating condition that affects millions of women globally. Gynica operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and biotechnology industries with its drug discovery and delivery innovations.
Strategic signal
In March 2024, Gynica announced the commencement of its first-in-human clinical trial for its novel IntraVag© treatment for endometriosis. This milestone is a significant validation of the company's therapeutic approach and signals a critical step forward in bringing its non-hormonal, intra-vaginal solution to market, potentially addressing a substantial unmet need in women's health.
Log in to access full profile ›Company Intelligence Q&A
- What is Gynica's primary focus?
- Gynica is a biotech company dedicated to improving the lives of women suffering from Endometriosis by developing safe, effective, non-hormonal, intra-vaginal therapeutic solutions.
- When was Gynica founded?
- Gynica was founded in January 2019.
- What is the status of Gynica's lead product?
- In March 2024, Gynica announced the initiation of its first-in-human clinical trial for its novel IntraVag© treatment for Endometriosis.
- What technology does Gynica utilize?
- Gynica utilizes its proprietary IntraVag© technology, which is a non-invasive, self-administered drug delivery platform.
- Has Gynica formed any strategic partnerships?
- In May 2022, Gynica partnered with HempStreet to develop phytopharma products. Additionally, in November 2018, Gynica announced a clinical trial partnership with Strainprint Technologies and Lumir Lab to establish a database of medical cannabis effects on women.